[1]李占山,宫思邈,廖 琦,等.G蛋白偶联胆汁酸受体1激动剂研究进展[J].陕西医学杂志,2025,54(3):413-423.[doi:DOI:10.3969/j.issn.1000-7377.2025.03.025]
 LI Zhanshan,GONG Simiao,LIAO Qi,et al.Advances in the study of TGR5 agonists[J].,2025,54(3):413-423.[doi:DOI:10.3969/j.issn.1000-7377.2025.03.025]
点击复制

G蛋白偶联胆汁酸受体1激动剂研究进展
分享到:

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
54
期数:
2025年3期
页码:
413-423
栏目:
综 述
出版日期:
2025-03-05

文章信息/Info

Title:
Advances in the study of TGR5 agonists
作者:
李占山1宫思邈2廖 琦1韩竹箴1王峥涛1
(1.上海中医药大学中药研究所,上海 201203; 2.上海中医药大学附属岳阳中西医结合医院,上海 200437)
Author(s):
LI Zhanshan1GONG Simiao2LIAO Qi1HAN Zhuzhen1WANG Zhengtao1
(1.Institute of Traditional Chinese Medicine,Shanghai University of Traditional Chinese Medicine,Shanghai 201203,China; 2.Yueyang Hospital of Integrated Traditional Chinese and Western Medicine Affiliated to Shanghai University of Traditional Chinese Medicine,Shanghai 200437,China)
关键词:
G蛋白偶联胆汁酸受体1 内源性胆汁酸及其类似物 合成小分子药物 结构修饰 天然产物 先导化合物
Keywords:
G protein-coupled bile acid receptor 1 Endogenous bile acids and their analogues Synthesis of small molecule drugs Structural modification Natural products Lead compound
分类号:
R 914
DOI:
DOI:10.3969/j.issn.1000-7377.2025.03.025
文献标志码:
A
摘要:
G蛋白偶联胆汁酸受体1(TGR5)激活通过多个信号转导通路影响糖脂代谢、能量代谢、炎症反应和内源性信号分子表达,在代谢性疾病和炎症性疾病的治疗中有着巨大的潜力。多个针对TGR5的药物已进入临床研究阶段,但由于不良反应明显,大规模临床应用受到限制。现将TGR5激动剂按内源性胆汁酸类、合成小分子药物和天然产物激动剂三类进行阐述,并针对TGR5靶点对天然产物结构优势进行分析,意在挑选合适的天然活性物质做作为先导化合物,为开发高效低毒的TGR5激动剂提供思路与参考。
Abstract:
The G protein-coupled bile acid receptor 1(TGR5)activation affects glycolipid metabolism,energy metabolism,inflammatory response and endogenous signaling molecule expression through multiple signaling pathways,which has great potential in the treatment of metabolic and inflammatory diseases.Multiple drugs targeting TGR5 have entered the clinical research stage,but their large-scale clinical use has been limited due to their obvious side effects.TGR5 agonists are classified into three categories:endogenous bile acids,synthetic small molecules and natural product agonists.We also analyzed the structural advantages of natural products for TGR5 targets,with the intention of selecting suitable natural active substances as lead compounds and providing ideas and references for the development of highly efficient and low-toxic TGR5 agonists.

参考文献/References:

[1] CHIANG J Y L,FERRELL J M.Bile acid receptors FXR and TGR5 signaling in fatty liver diseases and therapy[J].Am J Physiol Gastrointest Liver Physiol,2020,318(3):g554-g573.
[2] KATSUMA S,HIRASAWA A,TSUJIMOTO G.Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1[J].Biochem Biophys Res Commun,2005,329(1):386-390.
[3] SHI Y,SU W,ZHANG L,et al.TGR5 regulates macrophage inflammation in nonalcoholic steatohepatitis by modulating NLRP3 inflammasome activation[J].Front Immunol,2020,11:609060.
[4] DING L,YANG Q,ZHANG E,et al.Notoginsenoside Ft1 acts as a TGR5 agonist but FXR antagonist to alleviate high fat diet-induced obesity and insulin resistance in mice[J].Acta Pharm Sin B,2021,11(6):1541-1554.
[5] HUANG S,MA S,NING M,et al.TGR5 agonist ameliorates insulin resistance in the skeletal muscles and improves glucose homeostasis in diabetic mice[J].Metabolism,2019,99:45-56.
[6] LI W,ZHUANG T,WANG Z,et al.Red ginseng extracts ameliorate high-fat diet-induced obesity and insulin resistance by activating the intestinal TGR5-mediated bile acids signaling pathway[J].Phytomedicine,2023,119:154982.
[7] JIN G,YAO X,LIU D,et al.Inducible nitric oxide synthase accelerates nonalcoholic fatty liver disease progression by regulating macrophage autophagy[J].Immun Inflamm Dis,2023,11(12):e1114.
[8] VAN NIEROP F S,SCHELTEMA M J,EGGINK H M,et al.Clinical relevance of the bile acid receptor TGR5 in metabolism[J].Lancet Diabetes Endocrinol,2017,5(3):224-233.
[9] SINHA S R,HAILESELASSIE Y,NGUYEN L P,et al.Dysbiosis-induced secondary bile acid deficiency promotes intestinal inflammation[J].Cell Host Microbe,2020,27(4):659-670.e5.
[10] KAWAMATA Y,FUJII R,HOSOYA M,et al.A G protein-coupled receptor responsive to bile acids[J].J Biol Chem,2003,278(11):9435-9440.
[11] MARUYAMA T,MIYAMOTO Y,NAKAMURA T,et al.Identification of membrane-type receptor for bile acids(M-BAR)[J].Biochem Biophys Res Commun,2002,298(5):714-719.
[12] YANG F,MAO C,GUO L,et al.Structural basis of GPBAR activation and bile acid recognition[J].Nature,2020,587(7834):499-504.
[13] MA K,TANG D,YU C,et al.Progress in research on the roles of TGR5 receptor in liver diseases[J].Scand J Gastroenterol,2021,56(6):717-726.
[14] SORRENTINO G,PERINO A,YILDIZ E,et al.Bile acids signal via TGR5 to activate intestinal stem cells and epithelial regeneration[J].Gastroenterology,2020,159(3):956-968.e8.
[15] WATANABE M,HOUTEN S M,MATAKI C,et al.Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation[J].Nature,2006,439(7075):484-489.
[16] SASAKI T,WATANABE Y,KUBOYAMA A,et al.Muscle-specific TGR5 overexpression improves glucose clearance in glucose-intolerant mice[J].J Biol Chem,2021,296:100131.
[17] KEITEL V,HÄUSSINGER D.TGR5 in cholangiocytes[J].Curr Opin Gastroenterol,2013,29(3):299-304.
[18] CAO H,CHEN Z X,WANG K,et al.Intestinally-targeted TGR5 agonists equipped with quaternary ammonium have an improved hypoglycemic effect and reduced gallbladder filling effect[J].Sci Rep,2016,6:28676.
[19] LI T,CHIANG J Y.Bile acid signaling in metabolic disease and drug therapy[J].Pharmacol Rev,2014,66(4):948-983.
[20] FUNABASHI M,GROVE T L,WANG M,et al.A metabolic pathway for bile acid dehydroxylation by the gut microbiome[J].Nature,2020,582(7813):566-570.
[21] LIEU T,JAYAWEERA G,BUNNETT N W.GPBA:A GPCR for bile acids and an emerging therapeutic target for disorders of digestion and sensation[J].Br J Pharmacol,2014,171(5):1156-1166.
[22] YU D D,SOUSA K M,MATTERN D L,et al.Stereoselective synthesis,biological evaluation,and modeling of novel bile acid-derived G-protein coupled bile acid receptor 1(GP-BAR1,TGR5)agonists[J].Bioorg Med Chem,2015,23(7):1613-1628.
[23] KUMAR D P,ASGHARPOUR A,MIRSHAHI F,et al.Activation of transmembrane bile acid receptor TGR5 modulates pancreatic islet α cells to promote glucose homeostasis[J].J Biol Chem,2016,291(13):6626-6640.
[24] PELLICCIARI R,FIORUCCI S,CAMAIONI E,et al.6alpha-ethyl-chenodeoxycholic acid(6-ECDCA),a potent and selective FXR agonist endowed with anticholestatic activity[J].J Med Chem,2002,45(17):3569-3572.
[25] FIORUCCI S,DI GIORGIO C,DISTRUTTI E.Obeticholic acid:An update of its pharmacological activities in liver disorders[J].Handb Exp Pharmacol,2019,256:283-295.
[26] PELLICCIARI R,GIOIELLO A,MACCHIARULO A,et al.Discovery of 6alpha-ethyl-23(S)-methylcholic acid(S-EMCA,INT-777)as a potent and selective agonist for the TGR5 receptor,a novel target for diabesity[J].J Med Chem,2009,52(24):7958-7961.
[27] NAKHI A,MCDERMOTT C M,STOLTZ K L,et al.7-methylation of chenodeoxycholic acid derivatives yields a substantial increase in TGR5 receptor potency[J].J Med Chem,2019,62(14):6824-6830.
[28] 陈卫东,赵世振,王艳东,等 苯乙基咪唑类衍生物及其用途:CN111763173A[P/OL].2022-11-01[2024-11-08].https://www.cqvip.com/doc/patent/3238265114.
[29] DEHMLOW H,ERICKSON S D,MATTEI P,et al.1,2-pyridazine,1,6-pyridazine or pyrimidine-benzamide derivatives as GPBAR1 modulators:WO2013149977[P/OL].2013-10-10[2024-11-08].https://pubchem.ncbi.nlm.nih.gov/patent/WO2013149977-A1.
[30] LEWIS J G,LEADBETTER M R,CALDWELL J,et al.Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists:US2017174718[P/OL].2017-06-22[2024-11-08].https://pubchem.ncbi.nlm.nih.gov/patent/US-2017174718-A1.
[31] 邱曲真.5,5-二甲基环己-1-烯类衍生物及其在代谢性疾病中的应用:CN111303067A[P/OL].2020-06-19[2024-11-08].https://www.cqvip.com/doc/patent/1995350933.
[32] PRATT B,WANG T L,MARTIN R,et al.Triazole and imidazole derivatives for use as TGR5 agonists in the treatment of diabetes and obesity:WO2010093845 [P/OL].2010-08-19[2024-11-08].https://pubchem.ncbi.nlm.nih.gov/patent/WO-2010093845-A1.
[33] CHARTON J,DEPREZ B,LEROUX F,et al.Imidazol-or 1,2,4-triazol-derivatives and their use:WO2015189330[P/OL].2015-12-17[2024-11-08].https://pubchem.ncbi.nlm.nih.gov/patent/WO-2015189330-A1.
[34] MARTIN R E,BISSANTZ C,GAVELLE O,et al.2-phenoxy-nicotinamides are potent agonists at the bile acid receptor GPBAR1(TGR5)[J].ChemMedChem,2013,8(4):569-576.
[35] MIYATA S,KAWASHIMA Y,SAKAI M,et al.Discovery,optimization,and evaluation of non-bile acid FXR/TGR5 dual agonists[J].Sci Rep,2021,11(1):9196.
[36] PHILLIPS D P,GAO W,YANG Y,et al.Discovery of trifluoromethyl(pyrimidin-2-yl)azetidine-2-carboxamides as potent,orally bioavailable TGR5(GPBAR1)agonists:Structure-activity relationships,lead optimization,and chronic in vivo efficacy[J].J Med Chem,2014,57(8):3263-3282.
[37] CHOBANIAN H,DEMONG D,GUO Y,et al.Antidiabetic bicyclic compounds:US10662171[P/OL].2020-05-26[2024-11-08].https://pubchem.ncbi.nlm.nih.gov/patent/US-10662171-B2.
[38] PARK E J,CHOI J,LEE K C,et al.Emerging PEGylated non-biologic drugs[J].Expert Opin Emerg Drugs,2019,24(2):107-119.
[39] HOGUET V,LASALLE M,MAINGOT M,et al.Beyond the rule of 5:Impact of PEGylation with various polymer sizes on pharmacokinetic properties,structure-properties relationships of mPEGylated small agonists of TGR5 receptor[J].J Med Chem,2021,64(3):1593-1610.
[40] DUAN H,NING M,ZOU Q,et al.Discovery of intestinal targeted TGR5 agonists for the treatment of type 2 diabetes[J].J Med Chem,2015,58(8):3315-3328.
[41] CHEN T,REICH N W,BELL N,et al.Design of gut-restricted thiazolidine agonists of G protein-coupled bile acid receptor 1(GPBAR1,TGR5)[J].J Med Chem,2018,61(17):7589-7613.
[42] GENET C,SCHMIDT C,STREHLE A,et al.Redefining the TGR5 triterpenoid binding pocket at the C-3 position[J].ChemMedChem,2010,5(12):1983-1988.
[43] SATO H,GENET C,STREHLE A,et al.Anti-hyperglycemic activity of a TGR5 agonist isolated from Olea europaea[J].Biochem Biophys Res Commun,2007,362(4):793-798.
[44] LO S H,LI Y,CHENG K C,et al.Ursolic acid activates the TGR5 receptor to enhance GLP-1 secretion in type 1-like diabetic rats[J].Naunyn Schmiedebergs Arch Pharmacol,2017,390(11):1097-1104.
[45] HORIBA T,KATSUKAWA M,MITA M,et al.Dietary obacunone supplementation stimulates muscle hypertrophy,and suppresses hyperglycemia and obesity through the TGR5 and PPARγ pathway[J].Biochem Biophys Res Commun,2015,463(4):846-852.
[46] ONO E,INOUE J,HASHIDUME T,et al.Anti-obesity and anti-hyperglycemic effects of the dietary citrus limonoid nomilin in mice fed a high-fat diet[J].Biochem Biophys Res Commun,2011,410(3):677-681.
[47] YANG Z,LI J,XIONG F,et al.Berberine attenuates high glucose-induced fibrosis by activating the G protein-coupled bile acid receptor TGR5 and repressing the S1P2/MAPK signaling pathway in glomerular mesangial cells[J].Exp Cell Res,2016,346(2):241-247.
[48] GENET C,STREHLE A,SCHMIDT C,et al.Structure-activity relationship study of betulinic acid,a novel and selective TGR5 agonist,and its synthetic derivatives:potential impact in diabetes[J].J Med Chem,2010,53(1):178-190.
[49] LO S H,CHENG K C,LI Y X,et al.Development of betulinic acid as an agonist of TGR5 receptor using a new in vitro assay[J].Drug Des Devel Ther,2016,10:2669-2676.
[50] WANG X Y,ZHANG S Y,LI J,et al.Highly lipophilic 3-epi-betulinic acid derivatives as potent and selective TGR5 agonists with improved cellular efficacy[J].Acta Pharmacol Sin,2014,35(11):1463-1472.[51] YUN Y,ZHANG C,GUO S,et al.Identification of betulinic acid derivatives as potent TGR5 agonists with antidiabetic effects via humanized TGR5(H88Y)mutant mice[J].J Med Chem,2021,64(16):12181-12199.[52] ZHUO N,YUN Y,ZHANG C,et al.Discovery of betulinic acid derivatives as gut-restricted TGR5 agonists:Balancing the potency and physicochemical properties[J].Bioorg Chem,2024,144:107132.[53] WANG L Y,CHENG K C,LI Y,et al.Glycyrrhizic acid increases glucagon like peptide-1 secretion via TGR5 activation in type 1-like diabetic rats[J].Biomed Pharmacother,2017,95:599-604.[54] JIANG L S,LI W,ZHUANG T X,et al.Ginsenoside Ro ameliorates high-fat diet-induced obesity and insulin resistance in mice via activation of the G protein-coupled bile acid receptor 5 pathway[J].J Pharmacol Exp Ther,2021,377(3):441-451.[55] GUO N,TONG T,REN N,et al.Saponins from seeds of Genus Camellia:Phytochemistry and bioactivity[J].Phytochemistry,2018,149:42-55.[56] ZHU H,WANG K,CHEN S,et al.Saponins from Camellia sinensis seeds stimulate GIP secretion in mice and STC-1 Cells via SGLT1 and TGR5[J].Nutrients,2022,14(16):3413.[57] JÄGER S,TROJAN H,KOPP T,et al.Pentacyclic triterpene distribution in various plants-rich sources for a new group of multi-potent plant extracts[J].Molecules,2009,14(6):2016-2031.[58] CHIANESE G,GOLIN-PACHECO S D,TAGLIALATELA-SCAFATI O,et al.Bioactive triterpenoids from the caffeine-rich plants guayusa and maté[J].Food Res Int,2019,115:504-510.[59] JAFRI L,SALEEM S,CALDERWOOD D,et al.Naturally-occurring TGR5 agonists modulating glucagon-like peptide-1 biosynthesis and secretion[J].Peptides,2016,78:51-58.[60] POLS T W,AUWERX J,SCHOONJANS K.Targeting the TGR5-GLP-1 pathway to combat type 2 diabetes and non-alcoholic fatty liver disease[J].Gastroenterol Clin Biol,2010,34(4-5):270-273.[61] WANG L Y,CHENG K C,LI Y,et al.The Dietary furocoumarin imperatorin increases plasma GLP-1 levels in type 1-like diabetic rats[J].Nutrients,2017,9(11):1192.[62] KIRCHWEGER B,KRATZ J M,LADURNER A,et al.In silico workflow for the discovery of natural products activating the G protein-coupled bile acid receptor 1[J].Front Chem,2018,6:242.[63] GU M,FENG Y,CHEN Y,et al.Deoxyschizandrin ameliorates obesity and non-alcoholic fatty liver disease:Involvement of dual farnesyl X receptor/G protein-coupled bile acid receptor 1 activation and leptin sensitization[J].Phytother Res,2023,37(7):2771-2786.[64] CHI B,ZHANG M,SUN L,et al.Study on the hypotensive effect and mechanism of hawthorn(Crataegus pinnatifida)fruits and hyperoside in spontaneously hypertensive rats[J].Food Funct,2024,15(10):5627-5640.[65] ZHU H,WANG G,BAI Y,et al.Natural bear bile powder suppresses neuroinflammation in lipopolysaccharide-treated mice via regulating TGR5/AKT/NF-κB signaling pathway[J].J Ethnopharmacol,2022,289:115063.[66] HALKIAS C,DARBY W G,FELTIS B N,et al.Marine bile natural products as agonists of the TGR5 receptor[J].J Nat Prod,2021,84(5):1507-1514.

相似文献/References:

[1]龚卫锋,张养民.丙型肝炎不同基因型G蛋白偶联胆汁酸受体1含量变化及原因研究*[J].陕西医学杂志,2019,(9):1126.
 GONG Weifeng,ZHANG Yangmin..Changes of GPBAR1 in different genotypes of hepatitis c and its causes[J].,2019,(3):1126.

备注/Memo

备注/Memo:
[基金项目]国家自然科学基金资助国际(地区)合作与交流项目(81920108033)
更新日期/Last Update: 2025-03-05